INVESTOR RELATIONS

Overview

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.

Latest News

Summary Toggle NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

Sep 21, 2020 | Press Releases

EL SEGUNDO, Calif. --(BUSINESS WIRE)--Sep. 21, 2020-- NantKwest, Inc. (NASDAQ: NK), a ...

Read More
Summary Toggle Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH

Sep 10, 2020 | Press Releases

SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2020-- Brink Biologics, Inc. (“Brink”), a NantKw...

Read More
Summary Toggle NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

Aug 24, 2020 | Press Releases

Both companies agree to share equally in costs relating to COVID-19 therapeutics and v...

Read More

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.

Required fields denoted by an asterisk ().

Alert type
NantKwest End-of-Day Stock Quote Alert
NantKwest SEC Alert
NantKwest End-of-Day SEC Alert
NantKwest Calendar Alert
NantKwest News Alert
NantKwest Weekly Summary Alert
NantKwest Annual Report Alert

Data Provided by Refinitiv. Minimum 15 minutes delayed.

INVESTOR RELATIONS

Overview

Latest News

Summary ToggleNantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

Summary ToggleBrink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH

Summary ToggleNantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

Receive E-mail Alerts

Summary Toggle NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

Summary Toggle Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH

Summary Toggle NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics